|
Press Room
2008 Press Releases
TSX:V - IXS
NASD OTC:BB: IXSBF
June 2, 2008
InNexus Biotechnology Launches Competitive Summer Intern Program: LABapprentice
BRITISH COLUMBIA, Canada - 2 June 2008 - InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), this week began its LABapprentice program, a competitive summer intern program with a twist.
“I am very excited for the start of our Labapprentice Program this week,” Jeff Morhet, Committee Panel Member and InNexus Chairman & CEO said. “These selected interns may look forward to a challenging, but rewarding experience working side-by-side with scientists developing the next generation of cancer drugs."
Five interns were selected among a highly competitive group of applicants. They are Steve Berman, Arizona State University Bachelor of Science in Biological Sciences; Samuel Roden, Molecular and Cellular Biology, University of Arizona; Leandra Brettner, Engineering Mathematics and Molecular/Cellular Biology, University of Arizona; Kelsey Avery, Biochemistry and Molecular Biophysics, University of Arizona; and Barbara Beauchamp, Microbiology/Chemistry Major, University of Arizona.
For more information check out the first episode spotlighted via www.labapprentice.com where viewers can follow the progress of the Interns.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Contact:
Jeff Morhet
Chairman & Chief Executive Officer
InNexus Biotechnology Inc.
480-862-7500
|
|
|
